丘脑胶质母细胞瘤:临床表现、管理策略与结局
该回顾性研究纳入57例丘脑胶质母细胞瘤患者,中位年龄53岁,中位KPS评分80,术前47%存在脑积水。中位总生存期12.2个月;多因素分析中仅初诊KPS是生存的显著预测因素。作者认为其总生存期与不可切除的幕上脑叶胶质母细胞瘤相当,需改进治疗并考虑早期临床试验和积极初始治疗。
要点
- 丘脑胶质母细胞瘤患者中位总生存期为12.2个月。
- 初诊KPS是唯一显著的多因素生存预测因素。
- 术前47%患者存在脑积水,脑脊液分流与更好的总生存期单变量相关。
核心结论
- 丘脑胶质母细胞瘤的总生存期与不可切除的幕上脑叶胶质母细胞瘤相当。
- 年轻和初诊功能状态好的患者生存期改善。
- 肿瘤累及中脑不是负性预后因素。
- 需要改进治疗,应考虑早期参与临床试验和积极的初始治疗。
研究设计与样本
- 回顾性综述,纳入10年期间所有丘脑胶质母细胞瘤患者,共57例符合纳入标准。
- 收集中位年龄53岁、中位KPS评分80的临床表现、影像和结局数据。
- 采用卡方检验和Fisher精确检验比较肿瘤组间临床特征,采用Cox比例风险模型分析总生存期相关变量。
主要发现
- 最常见初诊症状为无力、意识模糊和头痛。
- 术前47%的患者存在脑积水。
- 47例接受立体定向活检,10例接受开颅手术。
- 中位总生存期为12.2个月。
- 单变量分析中,较高的KPS、较年轻年龄和脑脊液分流分别与更好的总生存期相关,而初诊时存在语言障碍与更差的生存期相关;多变量分析中仅初诊KPS是显著的生存预测因素。
临床怎么用
- 作者认为应考虑早期参与临床试验和积极的初始治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thalamic glioblastomas (GBMs) represent a significant neurosurgical challenge. In view of the low incidence of these tumors, outcome data and management strategies are not well defined. OBJECTIVE: To identify the natural history and factors associated with survival in patients with thalamic glioblastoma. METHODS: A retrospective review of all patients with thalamic glioblastoma over a 10-yr period was performed. Presenting clinical, radiological, and outcome data were collected. Chi-squared and Fisher's exact tests were used to compare clinical characteristics across tumor groups. Cox proportional hazard models were utilized to investigate variables of interest with regard to overall survival. RESULTS: Fifty-seven patients met inclusion criteria, with a median age of 53 and median Karnofsky Performance Scale (KPS) score of 80. The most common presenting symptoms were weakness, confusion, and headache. Hydrocephalus was present in 47% of patients preoperatively. Stereotactic biopsy was performed in 47 cases, and 10 patients underwent craniotomy. The median overall survival was 12.2 mo. Higher KPS, younger age, and cerebrospinal fluid (CSF) diversion were correlated with better overall survival univariately, respectively, while the presence of language deficits at initial presentation was associated with poorer survival. In multivariate analysis, the only significant predictor of survival was presenting KPS. CONCLUSION: The overall survival of patients with thalamic glioblastoma is comparable to unresectable lobar supratentorial GBMs. Younger patients and those with good presenting functional status had improved survival. Midbrain involvement by the tumor is not a negative prognostic factor. Improved therapies are needed, and patients should be considered for early trial involvement and aggressive upfront therapy.
引用
- Esquenazi Y, Moussazadeh N, Link TW, et al. Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. Neurosurgery. 2018. PMID: 28973417. doi:10.1093/neuros/nyx349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。